Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2019 Apr 26;12:3161–3170. doi: 10.2147/OTT.S192061

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2019 Shi et al.

This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).

PMC Copyright notice

NSCLC apoptosis induced by activated suicide gene therapy vector. H1299 (A and B), A549 (C) or H23 (D) cells were transfected with control vector (pTarget) or suicide gene therapy vector (pE9NS.G45α). At 24 hrs after transfection, the cells were exposed to 3 µM of cisplatin, 25 µM of resveratrol or 5 Gy of radiation. After 2 days, the cells were subjected to Annexin V-FITC/PI staining and analyzed by flow cytometry, or the protein lysis was collected for western blot analysis (E). Percentage of apoptotic cells is the sum of percentages of early- and late-phase apoptotic cells and is presented as mean ± SEM of three independent experiments. Statistics was performed by t-test with Welch’s correction to compare pTarget- and pE9NS.G45α-transfected samples after same stimulation (eg, pTarget+cisplatin vs pE9NS.G45α+cisplatin), * p<0.05; ** p<0.01.